Willingness to use and preferences for long‐acting injectable PrEP ...

Promises and potential pitfalls of long-acting injectable pre ...

This superior effectiveness likely resulted, at least partially, from improved adherence to injectable versus oral PrEP, as oral PrEP's efficacy ...

Advancing use of long-acting and extended delivery (LAED) HIV ...

Long-acting injectable cabotegravir. (CAB)-rilpivirine has ... Annual implants and injections were the next most preferred LA-ART options.

Study supports pricing long-acting injectable cabotegravir to ...

The analysis revealed that at a range of willingness-to-pay thresholds ($50,000-$300,000/QALY), CAB-LA for PrEP among MSM/TGW at high risk for ...

Transactional Sex and Preferences for Pre-Exposure Prophylaxis ...

Long-acting injectable PrEP may be an important HIV-prevention option for MSM who engage in transactional sex if this modality is proven effective. Subjects:.

Why is the roll-out of injectable PrEP taking so long? - Aidsmap

This is why, despite the technology transfer agreements negotiated with the pharmaceutical company ViiV, generic CAB-LA will probably not be ...

Untitled

Of those using/interested in using PrEP, nearly two-thirds indicated a desire to use long-acting injectable PrEP over oral PrEP while both groups highlighted ...

Expert insight: Long-acting injectable PrEP is a big step forward in ...

Share · learn their preferences regarding future long-acting injectable PrEP options · assess the feasibility of various models of delivering ...

Implementing LAI-PrEP in Ryan White CARE Act Clinics

Long-acting cabotegravir (CAB-LA) was shown to be superior to oral PrEP and safe and effective among cisgender women, cisgender men who have sex with men, and ...

ViiV Healthcare expands on real-world data supporting use of long ...

Analysis of cabotegravir + rilpivirine long-acting (CAB+RPV LA) in the real-world and across phase 3/3b studies: Findings from a large-scale ...

HIV Treatment and Prevention Long-Acting Modalities ... - YouTube

HIV Treatment and Prevention Long-Acting Modalities, Patient Preferences, & Financial Considerations. 149 views 9 months ago

Long-Acting HIV Treatment | CABENUVA (cabotegravir; rilpivirine)

It is not known if CABENUVA will harm your unborn baby. CABENUVA can remain in your body for up to 12 months or longer after the last injection. are ...

Coalition to Accelerate Access to Long-Acting PrEP - PrEPWatch

But the global health community moved too slowly and more than a decade later, only 5.67 million people have initiated oral PrEP use (cumulative number of ...

Worth a shot: Injectable PrEP for HIV prevention - CATIE.ca

First, the pharmaceutical company needs to apply to Health Canada for approval of long-acting cabotegravir for use as PrEP, and Health Canada ...

Preparing for Pharmacy-based Delivery of Long-Acting Injectable ...

Pharmacies as Innovative Settings for Promoting HIV PrEP Adherence. UCSF Center for AIDS Prevention Studies (CAPS) & Prevention Research ...

Gilead Presents Full PURPOSE 2 Data Results for Twice Yearly ...

Adherence to lenacapavir and to the placebo injections that were part of the oral PrEP study group was high: 91.0% of all trial participants ...

Making PrEP accessible: Updates on long-acting injectable options

The webinar was hosted by IAS – the International AIDS Society – on 30 March 2023, provided the latest updates on long-acting injectable ...

Pre-exposure prophylaxis for HIV prevention - Wikipedia

Pre-exposure prophylaxis for HIV prevention, commonly known as PrEP, is the use of antiviral drugs as a strategy for the prevention of HIV/AIDS by people ...

Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly ...

Adherence to lenacapavir and to the placebo injections that were part of the oral PrEP study group was high: 91.0% of all trial participants ...

Long-Acting HIV Prevention Tools

Currently, only one form of long-acting injectable PrEP has been approved by the U.S. Food and Drug Administration (FDA). But research continues ...

Twice-Yearly PrEP Shines in Early Study Results, But ... - TheBodyPro

Its unique feature is it can be administered through subcutaneous injection just once every six months. I think when we talk about long-acting ...